clinical trial · NCT04929236
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma·phase3·recruiting·n = 30
Pediatric Chronic Inflammatory Demyelinating PolyneuropathyPanzyga
brief summary
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
started
Oct 1, 2023
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Aug 5, 2026
official title
Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol